vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
Healthcare
$16.36 +1.47%
+$0.50 today
- Market cap
- $64.69M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
52W Low $14.00High $44.00
Volume 0.02M
Average 0.05M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$25.25M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$77.44M
FY 2025 · Annual
+47.2% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.73M) | (19.16M) | (20.25M) | (22.71M) | (31.08M) |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.36M | 0 | 1.58M | 2.76M | 3.78M |
| Change in Working Capital | 35K | 5.39M | 4.39M | (5.44M) | 1.89M |
| Accounts Receivables | 101K | (116K) | 71K | 40K | 0 |
| Inventory | (889K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.83M | (856K) | 2.93M | 0 | 1.53M |
| Other Working Capital | (1.01M) | 6.36M | 1.39M | (5.48M) | 362K |
| Other Non-Cash Items | (4.06M) | (1.56M) | (4.89M) | (10K) | 142K |
| Operating Cash Flow | (19.31M) | (15.25M) | (19.08M) | (25.31M) | (25.26M) |
| Capital Expenditures | 0 | (21K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 4.4M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 4.4M | 0 | 0 |
| Other Investing Activities | 0 | 0 | (4.4M) | 0 | 0 |
| Investing Cash Flow | 0 | (21K) | 4.4M | 0 | 0 |
| Debt Repayment | 172K | (808K) | (33K) | (191K) | (392K) |
| Common Stock Issued | 26.76M | 14.79M | 12.03M | 52.8M | 77.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 47K | 0 | 0 | 0 | 341K |
| Financing Cash Flow | 26.98M | 13.98M | 12M | 52.61M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.67M | (1.29M) | (2.68M) | 27.3M | 52.19M |
| Free Cash Flow | (19.31M) | (15.27M) | (19.08M) | (25.31M) | (25.26M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$31.1M
+ D&A$16.0K
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
+ Working Capital$1.9M
+ Other Non-Cash$142.0K
= Operating Cash Flow-$25.3M
- Capex$0
= Free Cash Flow-$25.3M
Analysis
FY2025 free cash flow is -$25.3M. FCF conversion is 81.3% of net income. Operating cash flow was -$25.3M, with capex of $0. The largest bridge item is Stock-Based Comp at $3.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 8, 2026 | |
| 8-K | Current report | Oct 6, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 |
Does VTVT generate free cash flow?
vTv Therapeutics Inc. (VTVT) generated -$25.25M of free cash flow in fiscal 2025.
How much operating cash flow does VTVT produce?
Operating cash flow was -$25.25M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.